The Cystic Fibrosis
Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a
compound that targets a non-CFTR chloride channel in lung cells. If successful,
the drug could help mucus become more hydrated and easier to clear from the
lungs of all people with CF, regardless of their CFTR mutations.